AbCellera Biologics Inc. (ABCL)
$13.64
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Key data on ABCL
Market cap
$4.42B
EPS
-0.48
P/E ratio
--
Price to sales
61.41
Dividend yield
--
Beta
1.410007
Price on ABCL
Previous close
$12.83
Today's open
$12.67
Day's range
$12.65 - $13.65
52 week range
$2.75 - $15.02
Profile about ABCL
CEO
Carl Hansen
Employees
586
Headquarters
Vancouver, BC
Exchange
Nasdaq Global Select
Shares outstanding
323905529
Issue type
Common Stock
Popular stocks like ABCL
ABCL industries and sectors
Healthcare
Biotechnology & Life Sciences
News on ABCL
AbCellera to Present at Upcoming Investor Conferences in November 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November 2026.
Business Wire • Oct 22, 2026
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
Business Wire • Oct 8, 2026
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
Business Wire • Oct 1, 2026
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Zacks Investment Research • Sep 22, 2026
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
Business Wire • Sep 16, 2026
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
Business Wire • Sep 2, 2026
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
Benzinga • Aug 25, 2026
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
Seeking Alpha • Aug 17, 2026
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
Business Wire • Aug 13, 2026
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
Benzinga • Aug 12, 2026
¹ Disclosures
Invest in AbCellera Biologics Inc.
Open an M1 investment account to buy and sell AbCellera Biologics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.